Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
4,664.00    -214.00 (-4.39%)
Bid:
4,682.00
Ask:
4,686.00
Spread: 4.00 (0.085%)
Market Cap: £17.62b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Acquisitions

25 Oct 2023 07:00

RNS Number : 1552R
Halma PLC
25 October 2023
 

Halma plc ('Halma' or the 'Group')

Acquisitions

Halma, the global group of life-saving technology companies, today announces that it has completed two bolt-on acquisitions for an aggregate maximum total consideration of approximately £46.5m.

 

In the Environmental and Analysis sector, Halma company, Alicat Scientific, Inc. (Alicat), has acquired the Alpha Instrumatics Group (Alpha Instrumatics).

 

Based in Bradford, UK, Alpha Instrumatics designs and manufactures devices for high-precision measurement of trace moisture found in gases. Trace moisture analysis allows the safer operation of industrial equipment, more efficient transfer of hydrocarbons, and more accurate detection of pollutants. Alpha Instrumatics' devices are used in growth markets, including the industrial gas and aerospace markets, as well as industries aligned to the new energy transition. This acquisition extends Alicat's product offering in its existing and adjacent end markets.

 

The initial cash consideration for Alpha Instrumatics is £31m, on a cash- and debt-free basis, which will be funded from Halma's existing facilities. Additional earn-out considerations are payable in cash, based on its performance over each of the two financial years to 31 March 2025, up to an aggregate maximum of £5.5m. Alpha Instrumatics' consolidated unaudited revenue for the 12 months to 30 September 2023 was £7.8m, with Return on Sales substantially above the upper end of Halma's target range of 18-22%.

 

In the Healthcare sector, Halma company, IZI Medical Products LLC (IZI), has acquired AprioMed AB (AprioMed). AprioMed designs, manufactures and distributes medical devices used for bone biopsies. This acquisition expands IZI's offerings for minimally invasive procedures, complementing its products used to diagnose and treat cancer.

 

The consideration for AprioMed is SEK130m (approximately £10m) on a cash- and debt-free basis, which is funded from Halma's existing facilities. AprioMed's unaudited revenue for the 12 months to 31 March 2023 was SEK40.0 (approximately £3.0m), with Return on Sales above Halma's target range of 18-22%.

Marc Ronchetti, Group Chief Executive of Halma, commented:

 

"Our companies have access to Halma expertise and capital to support their growth locally and internationally. These bolt-on acquisitions are strongly aligned with our purpose and financial model and will bring complementary capabilities to Alicat and IZI Medical, including new technologies and broader market reach. We are excited by the opportunities we see for new standalone companies to join Halma and for our existing companies to add new capabilities through bolt-on acquisitions to grow their businesses over the long term."

 

For further information, please contact:

Halma plc

Marc Ronchetti, Group Chief Executive +44 (0)1494 721111

Steve Gunning, Group Chief Financial Officer

Charles King, Head of Investor Relations +44 (0) 7776 685948

Clayton Hirst, Director of Corporate Affairs +44 (0) 7384 796 013

MHP

Oliver Hughes / Rachel Farrington / Ollie Hoare +44 (0)20 3128 8100 

A copy of this announcement, together with other information about Halma, is available at www.halma.com.

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day. Its purpose defines the three broad markets it operates in:

· Safety - Protecting people's safety and the environment as populations grow, and enhancing worker safety.

· Environment - Addressing the impacts of climate change, pollution and waste, protecting life-critical resources and supporting scientific research.

· Health - Meeting the increasing demand for better healthcare as chronic illness rises, driven by growing and ageing populations and lifestyle changes.

It employs over 8,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

Halma has been named as one of Britain's Most Admired Companies for the past five years.

For more information www.halma.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUSSVROWURUAA
Date   Source Headline
1st Apr 20083:34 pmRNSTotal Voting Rights
28th Mar 20084:04 pmRNSTreasury Stock
27th Mar 20089:47 amRNSHolding(s) in Company
25th Mar 20086:07 pmRNSDirector/PDMR Shareholding
14th Mar 200811:42 amRNSDirector/PDMR Shareholding
3rd Mar 20084:19 pmRNSTotal Voting Rights
29th Feb 20084:40 pmRNSHolding(s) in Company
19th Feb 20082:46 pmRNSHolding(s) in Company
18th Feb 200811:45 amRNSHolding(s) in Company
18th Feb 20089:59 amRNSTreasury Stock
14th Feb 20087:00 amRNSInterim Management Statement
5th Feb 20081:08 pmRNSHolding(s) in Company
1st Feb 20083:17 pmRNSBlocklisting Interim Review
1st Feb 20083:15 pmRNSTotal Voting Rights
9th Jan 20083:59 pmRNSTreasury Stock
8th Jan 200811:12 amRNSHolding(s) in Company
4th Jan 20081:06 pmRNSHolding(s) in Company
2nd Jan 20084:47 pmRNSTotal Voting Rights
21st Dec 200711:25 amRNSDirector Declaration
20th Dec 20077:00 amRNSAcquisition
4th Dec 20073:09 pmRNSDirector/PDMR Shareholding
4th Dec 200711:50 amRNSTotal Voting Rights
29th Nov 200711:23 amRNSDoc re. Half year report 2007
29th Nov 20077:00 amRNSInterim Results
16th Nov 20074:18 pmRNSNotice of Results
6th Nov 20071:03 pmRNSHolding(s) in Company
2nd Nov 200711:48 amRNSTotal Voting Rights
25th Oct 20077:00 amRNSPost-Close Trading Update
5th Oct 20074:02 pmRNSTreasury Stock
1st Oct 200710:00 amRNSTotal Voting Rights
27th Sep 200710:22 amRNSTreasury Stock
19th Sep 20079:38 amRNSDirector/PDMR Shareholding
3rd Sep 20073:08 pmRNSTotal Voting Rights
7th Aug 20075:35 pmRNSTreasury Stock
3rd Aug 20075:33 pmRNSDoc re. AGM 2007 Resolutions
3rd Aug 20074:15 pmRNSHolding(s) in Company
2nd Aug 200711:34 amRNSDirectorate Change
1st Aug 20077:00 amRNSInterim Management Statement
31st Jul 200710:22 amRNSTotal Voting Rights
30th Jul 200712:40 pmRNSHolding(s) in Company
27th Jul 20074:46 pmRNSHolding(s) in Company
26th Jul 200711:36 amRNSAnnual Information Update
20th Jul 200712:39 pmRNSBlocklisting Interim Review
11th Jul 20073:13 pmRNSHolding(s) in Company
10th Jul 20072:15 pmRNSHolding(s) in Company
9th Jul 200712:07 pmRNSDirector/PDMR Shareholding
3rd Jul 20072:53 pmRNSDirector/PDMR Shareholding
29th Jun 200711:57 amRNSTotal Voting Rights
27th Jun 20072:50 pmRNSDirector/PDMR Shareholding
27th Jun 20079:50 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.